| Symbol | Company | Owner | Relationship | Date | Transaction | Cost | # Shares | Value ($) | Total Shares | Filing | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PSTX | Poseida Therapeutics, Inc. | Gergen Mark J | Executive Chairman | Feb 01, 2024 | Option Exercise | $3.41 | 47,162 | 160,822 | 685,448 | Feb 02, 2024, 08:51 PM | |
| PSTX | Poseida Therapeutics, Inc. | Gergen Mark J | President and CEO | Feb 01, 2023 | Option Exercise | $7.00 | 31,819 | 222,733 | 330,314 | Feb 03, 2023, 04:16 PM | |
| AMLN | AMYLIN PHARMACEUTICALS INC | Gergen Mark J | SVP, Corporate Development | Aug 08, 2012 | Option Exercise | $31.00 | 7,974 | 247,194 | 1,360 | Aug 10, 2012, 06:37 PM | |
| AMLN | AMYLIN PHARMACEUTICALS INC | Gergen Mark J | SVP, Corporate Development | Aug 08, 2012 | Option Exercise | $31.00 | 2,609 | 80,879 | 473 | Aug 10, 2012, 06:37 PM | |
| AMLN | AMYLIN PHARMACEUTICALS INC | Gergen Mark J | SVP, Corporate Development | Aug 08, 2012 | Option Exercise | $31.00 | 171,112 | 5,304,472 | 53,181 | Aug 10, 2012, 06:37 PM | |
| AMLN | AMYLIN PHARMACEUTICALS INC | Gergen Mark J | SVP, Corporate Development | Jul 25, 2012 | Option Exercise | $14.62 | 936 | 13,684 | 64,750 | Jul 26, 2012, 08:06 PM | |
| AMLN | AMYLIN PHARMACEUTICALS INC | Gergen Mark J | SVP, Corporate Development | Mar 01, 2012 | Sale | $17.11 | 1,846 | 31,585 | 53,814 | Mar 02, 2012, 07:45 PM | |
| AMLN | AMYLIN PHARMACEUTICALS INC | Gergen Mark J | SVP, Corporate Development | Feb 23, 2012 | Sale | $17.03 | 7,518 | 128,033 | 54,826 | Feb 24, 2012, 05:02 PM | |
| AMLN | AMYLIN PHARMACEUTICALS INC | Gergen Mark J | SVP, Corporate Development | Feb 08, 2012 | Option Exercise | $16.47 | 3,133 | 51,601 | 42,344 | Feb 10, 2012, 08:54 PM |
Menu